Invest in the company revolutionizing the $180B industry for osteoarthritis
While global trends can sometimes seem unpredictable (who knew 2020 would be dominated by a pandemic quarantine and TikTok trends?), there's one thing that everyone can predict: healthcare will always be a sector that is in high demand sustained by innovation.
That's why it pays to invest in startup biotech companies: not only are you helping to improve the health and well-being of millions of people, novel pharmaceutical research and development addresses a multi-billion dollar market that everyone on the planet is a part of. And in the case of osteoarthritis, it's a $180 billion industry that stands to impact the lives of an estimated 25 percent of American adults by 2030. Osteoarthritis is a debilitating disease that is caused by the erosion of cartilage within the joints, and is a major problem among the elderly and athletes. No treatments exist that actually address the root cause of the disease (hyper-active enzymes called proteases), and there is clearly an enormous unmet need for an effective treatment that doesn’t just mask the joint pain and inflammation caused by osteoarthritis
Enter Cytonics - a biotech research and development company dedicated to creating diagnostics and treatments for osteoarthritis. For just $2 a share, you can fund the development of a novel, “first-in-class” therapy that could relieve millions of Americans from arthritis and give them their quality of life back. On a personal level, you are being given the opportunity to participate in investment at a stage usually reserved for venture capital or the mega-rich. With over $15 million raised from over 100 public and private investors, including the National Institute of Health and Johnson and Johnson, Cytonics has a proven track record of developing therapeutics through the FDA regulatory process and commercializing new therapies for osteoarthritis.
Why does Cytonics consider itself "the future of regenerative medicine"? Rather than focusing on symptoms of osteoarthritis (joint pain and inflammation) like NSAIDs, hyaluronic acid, and corticosteroids do, Cytonics has developed a novel approach that addresses the root cause of osteoarthritis on the molecular level. The key to their innovation resides in the therapeutic potential of a naturally occurring blood protein called Alpha-2-Macroglobulin (A2M), that can target and inhibit the molecular forces (proteases) that degrade cartilage in arthritic joints. The company’s first-generation treatment, the APIC therapy, extracts and concentrates the natural A2M from a patient’s own blood for injection in damaged joints. This therapy has been in the market since 2015 and has successfully treated over 8,000 patients to-date.
Cytonics' first-in-class drug, “CYT-108”, is a protein therapy based on the naturally occurring A2M found in the body. Using the natural A2M gene sequence as a starting point, Cytonics genetically engineered CYT-108 to increase its effectiveness in preventing cartilage damage by targeting and inhibiting the destructive proteases. When CYT-108 bonds with proteases, it triggers encapsulation and excretion by the body's immune cells, which rescues the body's cartilage from further damage. The results from preliminary preclinical data are astounding – CYT-108 was able to restore damage caused by osteoarthritis by up to 60 percent.
Cytonics’ mission to develop first-in-class osteoarthritis treatments has already seen success, with over 8,000 remedied patients remedied by their APIC therapy. Cytonics has given these patients their lives back, and CYT-108 is poised to be a cutting edge therapy for treating osteoarthritis. The company’s identification of the naturally occurring A2M molecule and the development of CYT-108 has the power to help millions of people, but reaching them is only possible with adequate investment and support.
By investing in Cytonics, you not only support leading scientists and stand side-by-side with the NIH and Johnson and Johnson, but you also support the millions of American who will begin to experience osteoarthritis within the coming decade. An investment in Cytonics is an investment in novel biotechnology research and development that has the potential to disrupt the regenerative medicine industry. For a limited time, you can join their growing list of supporters now for just $2 a share and be a part of an endeavor to improve lives in an industry that is experiencing tremendous growth.